Paragon Capital Management Inc Gilead Sciences, Inc. Transaction History

Paragon Capital Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Sep 26, 2024	SELL	$73.94 - $80.67 $1.11 Million - $1.21 Million	-14,991 Closed	0 $0
Q2 2023 Sep 26, 2024	SELL	$76.01 - $86.7 $505,162 - $576,208	-6,646 Reduced 30.72%	14,991 $1.16 Billion
Q1 2023 Sep 26, 2024	BUY	$77.31 - $88.08 $592,349 - $674,868	7,662 Added 54.83%	21,637 $1.8 Billion
Q4 2022 Sep 25, 2024	BUY	$62.32 - $89.47 $870,922 - $1.25 Million	13,975 New	13,975 $1.2 Billion

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Paragon Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Paragon Capital Management Inc with notifications on news.